Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGF-C AAV
- Development stage
- Preclinical
- Lead developer
- University of Illinois Chicago
- Modality
- Gene Therapies
- Administration
- Intrathecal, Intramyocardial, Intravenous
01
Overview
VEGF-C AAV is an experimental gene therapy that utilizes adeno-associated virus (AAV) vectors to deliver the vascular endothelial growth factor C (VEGF-C) gene. Upon administration, the vector induces the expression of VEGF-C protein, which primarily binds to and activates the vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3. This activation promotes lymphangiogenesis and has been investigated for various therapeutic applications, including enhancing lymphatic drainage in the brain following stroke or injury, stimulating cardiac lymphangiogenesis after myocardial infarction, and improving cerebrospinal fluid drainage. Conversely, research has also indicated that chronic VEGF-C signaling via AAV delivery can exacerbate conditions like non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) by promoting pathological angiogenesis and fibrosis. Currently, it remains a research tool and preclinical candidate without a commercial sponsor.
- Other names
- adeno-associated virus-vascular endothelial growth factor C
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)NRP1 (Neuropilin-1)
Beyond the preview
Go deeper on VEGF-C AAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGF-C AAV.